Temporomandibular joint involvement in Juvenile Idiopathic Arthritis: reliability and validity of a screening protocol for the rheumatologist

Table 1 Patient characteristics

	n	Mean	SD	Min - Max
Examined	76
Enrolled (F:M)	74 (2.4:1)
Age (SD) yrs		11.9	3.8
Age at onset (SD) yrs		7.5	3.9
Disease duration (SD) yrs		4.5	3.4
JIA diagnosis:
Oligo ANA pos	17/23%
Oligo ANA neg	15/20.3%
Oligo extended	6 /8.1%
Poly RF pos	16/21.6%
Poly RF neg	8/10.8%
Systemic JIA	8 (10.8)%
ERA HLA B27 pos	3/4%
Psoriatic Arthritis	1/1.4%
Medication:
NSAID	36/48.6%
Systemic steroids	4/5.4%
DMARDS	41/55.4%
Biologics	22/29.7%
Orthodontic tx	7/9.5%
JADAS-27	74	3.6	5.8	0 – 37.5
MMO	74	45.3	7.7	25 – 60
MMO age ≤ 10	27	43.6	5.4	25 – 52
MMO age > 10	47	46.3	8.7	25 – 60
MMO ≤ 40	21	35.9	4.2	25 – 40
MMO ≤ 35	8	32.1	4.5	25 – 35
MMO ≤ 30	2	-	-	25 – 27

Number of patients referred to as n / % (unless indicated otherwise), and MMO as mm
Pt: patients; F: female; M: male; yrs: years, SD = standard deviation, n = number of patients. ANA: anti-nuclear antibodies; oligo: oligoarticular; poly: polyarticular; ERA: enthesitis-related arthritis; PsoA: psoriatic arthritis; NSAIDs: non-steroidal anti-inflammatory drugs; DMARDs: disease modifying anti-rheumatic drugs. Orthodontic tx: coincidental orthodontic treatment (patients being in treatment and wearing appliances not for JIA related TMJ issues). MMO: maximum mouth opening; JADAS-27: Juvenile Arthritis Disease Activity Score.

ISSN: 1546-0096